Ronan A. Murphy PhD

Irish in Berlin. Microbiologist. Post-doc in Rolff Lab, Freie Universität Berlin. #AMR #AMPs. PhD from @ImperialNHLI Davies Lab. he/him

[Ronan A. Murphy PhD @Mic_Ro_]

Now, (very) peer-reviewed and in the current issue of @JournalSpectrum

Improved efficacy of tobramycin ✅
By an Antimicrobial peptide ✅
Against clinical P. aeruginosa ✅
AMP a drug already in clinical use ✅

https://t.co/IaJqQmk7MI

[Micaela @MicaelaMossop]

Exciting Friday news! Check out our paper in the Blue Journal to find out more about clinical impacts of chronic Pseudomonas/Staph co-infections in CF https://t.co/RRT8MDbmQ5
Thanks to ALL the co-authors particularly @janedaviescf @DrLauraNolan & Jonathan Ish-Horowicz for stats

[Ronan A. Murphy PhD @Mic_Ro_]

Overall this adds depth to our knowledge of GA’s mechanism of antimicrobial action and gives positive indications in terms of future resistance development to a peptide drug and for the potential repurposing of GA as an antimicrobial

[Ronan A. Murphy PhD @Mic_Ro_]

Very happy that this is out in @npjAMR, from myself and @janedaviescf. In collaboration with @gLarrouyM_Lab, @DrLauraNolan, @bugsinblood, @Leahcuthbertso4 and others.

[npj Antimicrobials and Resistance @npjAMR]

Hot off the press in @npjAMR

@Mic_Ro_ et al., show the mechanism of action of antimicrobial peptide glatiramer acetate in Pseudomonas aeruginosa🦠💊

https://t.co/wx4hQyqU6n

(1/6)

[Ronan A. Murphy PhD @Mic_Ro_]

We used lab strains of P. aeruginosa as well as a panel of clinical isolate from people with Cystic Fibrosis.

[npj Antimicrobials and Resistance @npjAMR]

Hot off the press in @npjAMR

@Mic_Ro_ et al., show the mechanism of action of antimicrobial peptide glatiramer acetate in Pseudomonas aeruginosa🦠💊

https://t.co/wx4hQyqU6n

(1/6)

[Claire Edmondson @claireedmo1]

Excited to share the most recent paper from my PhD CLIMB-CF. Again massive thanks to all the sites&families who were involved & @cftrust @CFCanada and @janedaviescf
#climbcf #nhli #imperialcollegelondon #WomenInSTEM #phdlife #cftrust #cfremotemonitoring

https://t.co/it9CnBFEyW

[Ronan A. Murphy PhD @Mic_Ro_]

This is a great opportunity with a really great team. Very interesting work and a bunch of lovely people!

[Luke Allsopp @luke_allsopp]

🚨Research Technician Opportunity
Come and join the team of @janedaviescf to work on #Microbiology #Pseudomonas #CF #AMR @ImperialNHLI @ImperialMed Apply by the 1st
Great boss and team!
Please RT https://t.co/wc5upvXM2C

[Luke Allsopp @luke_allsopp]

Latest from the lab! Digging deep into the #T6SS of #Pseudomonas with some old school comparative #genomics in #clinical strains. New #effectors and differences in #complements of effectors @ImperialNHLI @ImperialMed @janedaviescf @FrontMicrobiol https://t.co/gSeSw82G4w

[Alice Collins @AlColls]

Starting the new year right with our story being published in @FrontMicrobiol today! Give our #T6SS #Pseudomonas effector diversity in clinical isolates study a read! #microbiology #phdlife @luke_allsopp, @janedaviescf @Mic_Ro_ https://t.co/mlAh3U93Hf

[Ronan A. Murphy PhD @Mic_Ro_]

Tayto says Happy New Year (warily)!

[Luke Allsopp @luke_allsopp]

Come read about #microbial #warfare in #bacteria Latest out from @DrLauraNolan and myself @luke_allsopp @ImperialNHLI In the seminar #Pseudomonas book series #CDI #T6SS #pyocin #colicin even a little on #quorumsensing https://t.co/jvaovthlG5

[Christopher Short @PhysiologyChris]

Extremely happy this is out and available on open access. @janedaviescf @ImperialNHLI @RBandH

[Ronan A. Murphy PhD @Mic_Ro_]

Day 2 of symposium on resistance at Tiermedizinisches Zentrum für Resistenzforschung in Berlin

[Ronan A. Murphy PhD @Mic_Ro_]

@tcoenye Growth Rates has lag time as one of its outputs after curve fitting. It has to be run from the command line but the documentation is pretty thorough

https://t.co/nGS3GNTloO

[Ronan A. Murphy PhD @Mic_Ro_]

5271 days between publication dates of first author papers must be some kind of record!

https://t.co/RYGSIOOg0D

[Ronan A. Murphy PhD @Mic_Ro_]

Lookee here! A pre-print! From myself and @janedaviescf on breaking antibiotic resistance in CF Pseudomonas using a repurposed drug. With thanks to co-authors, including @Matt_loves_bugs @bugsinblood

[bioRxiv Microbiology @biorxiv_micrbio]

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin Against Cystic Fibrosis Pseudomonas aeruginosa https://t.co/JAKzyYZGng #biorxiv_micrbio

[Ronan A. Murphy PhD @Mic_Ro_]

Now, (very) peer-reviewed and in the current issue of @JournalSpectrum

Improved efficacy of tobramycin ��
By an Antimicrobial peptide ✅
Against clinical P. aeruginosa ✅
AMP a drug already in clinical use ✅

https://t.co/IaJqQmk7MI